| Combination Radiotherapy and Radiopharmaceutical Therapy Treatment Planning for Thyroid Cancer (NCT04892303) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2021-03-17 |
| Inolitazone Dihydrochloride and Paclitaxel in Treating Patients With Advanced Anaplastic Thyroid Cancer (NCT02152137) | Alliance for Clinical Trials in Oncology | 2014-12-30 |
| Dabrafenib With or Without Trametinib in Treating Patients With Advanced Differentiated Thyroid Cancer (NCT01723202) | Bhavana Konda | 2012-11-07 |
| Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer (NCT01502410) | National Cancer Institute (NCI) | 2012-01-01 |
| Iodine I 131 and Pazopanib Hydrochloride in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer Previously Treated With Iodine I 131 That Cannot Be Removed By Surgery (NCT01413113) | University of Washington | 2011-12-01 |
| Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer (NCT00519896) | University of Washington | 2007-07-01 |
| Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck Cancer (NCT00470496) | Roswell Park Cancer Institute | 2006-10-19 |
| Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer (NCT00134043) | National Cancer Institute (NCI) | 2005-12-01 |
| Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer (NCT00126568) | National Cancer Institute (NCI) | 2005-06-01 |
| Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer (NCT00118248) | National Cancer Institute (NCI) | 2004-12-01 |
| Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy (NCT00104871) | National Cancer Institute (NCI) | 2004-12-01 |
| Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer (NCT00095693) | National Cancer Institute (NCI) | 2004-10-01 |
| Romidepsin in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive Iodine (NCT00098813) | National Cancer Institute (NCI) | 2004-10-01 |
| Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131 (NCT00085293) | National Cancer Institute (NCI) | 2004-05-01 |
| Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer (NCT00068497) | National Cancer Institute (NCI) | 2003-08-01 |
| Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu (NCT00004074) | National Cancer Institute (NCI) | 1999-08-01 |